Healthcare / Medical Instruments & SuppliesParis
$0.13
+0.00 (+1.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-3.3M · quality 59.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-9.7%
↓Gross Margin
72.5%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+18.7%
FCF CAGR
—
FCF margin
-1.3%
FCF / Net income
0.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $12.4M · net income $-2.2M · FCF $-163000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $12.4M | $12.4M | $11.9M | $10.5M | $7.4M |
| Net Income | $-2.2M | $-2.2M | $-3.9M | $-6.5M | $-3.1M |
| EBITDA | $-727000.00 | $-727000.00 | $-1.6M | $-4.6M | $-2.1M |
| EPS | -0.06 | -0.06 | -0.00 | -0.82 | — |
| Gross Margin | 72.5% | 72.5% | 70.7% | 74.9% | 80.5% |
| Operating Margin | -12.9% | -12.9% | -7.4% | -40.6% | -42.9% |
| Net Margin | -18.0% | -18.0% | -32.3% | -61.9% | -42.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.07 | 0.14 | 0.13 |
| Current Ratio | 2.16 | 2.16 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-163000.00 | $-163000.00 | $-3.3M | $-7.3M | $-1.6M |
| Returns | |||||
| ROE | -9.7% | -9.7% | -15.9% | -34.2% | -14.3% |
| Valuation | |||||
| P/B | 0.00 | 0.00 | 0.52 | 0.00 | 1150.93 |
| Growth & Yield | |||||
| Revenue Growth | 4.0% | 4.0% | 13.6% | 41.5% | — |
| EPS Growth | -238396.3% | -238396.3% | 100.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.00 → -0.06
Residual
-7.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.